Subject
Transplantation,Hematology
Reference8 articles.
1. Alatrash G, de Lima M, Hamerschlak N, et al. Myeloablative, reduced toxicity IV busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients in the sixth through eighth decades of life. Biol Blood Marrow Transplant. in press.
2. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS;Andersson;Biol Blood Marrow Transplant,2008
3. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide;Bredeson;Biol Blood Marrow Transplant,2008
4. A randomized, phase III trial comparing BuCy and BuFlu as a myeloablative conditioning regimen;Kim;J Clin Oncol,2011
5. A risk score for mortality after allogeneic hematopoietic cell transplantation;Parimon;Ann Intern Med,2006
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献